Latest Headlines

Latest Headlines

Japan's Mitshubishi Pharma loses Indian diabetes case

India's patent office dealt a blow to Mitsubishi Pharma by denying the Japanese company's application to patent the new diabetes drug teneligliptin, which will allow generic makers to move ahead with their plans to manufacture and market the drug.

Lupin hopes for more U.S. approvals as earnings drop 35%

Indian drug giant Lupin said it hopes to see more of its drugs approved by the U.S. FDA before the end of the year, according to a report by Reuters.

India's Lupin in price rise spotlight for diabetes drug in the U.S.

India's Business Standard, citing brokerage reports, said the domestic drug company Lupin has raised the price for diabetes drug Fortamet in the U.S. by 200%, though that still puts it below rival Valeant Pharmaceuticals.

Lupin gets first U.S. manufacturing base with buyout of GAVIS

India's Lupin has landed its first manufacturing site in the U.S. with an $880 million deal to buy a small generics maker in New Jersey that specializes in niche products including dermatology controlled substances.

Lupin antibiotic products banned by Brazil

Lupin, which has been expanding its manufacturing and marketing footprint internationally via M&A, moved on Brazil in May with the acquisition of generics and OTC maker Medquímica Indústria Farmacêutica. But new markets mean new regulations, and the Indian company has been tripped by some issues that led Brazil to ban some of Lupin's antibiotic products.

India's Lupin gets Russian production site in deal for Biocom

While recent problems in Russia's economy have thrown some deals off course, Western drugmakers in the last several years have built or bought production capacity in Russia to tap what has been seen as an important emerging market. India's Lupin jumped into that market, picking up a company that will give it a production toehold there.

India's Gujarat state drugmakers speed up biosimilar race

Drug companies in India's leading industrial state of Gujarat, the base of Prime Minister Narendra Modi, are stepping up efforts to crack the domestic market for biosimilars as well as abroad, Business Standard reports.

Cipla, Lupin in UCB U.S. generics bid as India-linked M&A heats up

India's Cipla and Lupin made first-round bids for the U.S. generics business of Belgium's UCB, Kremers Urban Pharmaceuticals, according to sources cited by Bloomberg, showing that domestic players are eagerly looking abroad to boost sales.

UCB reportedly gets bids for Kremers Urban unit from Cipla and Lupin

After having to call off a $1.5 billion deal last year to sell its U.S.-based generics business, Belgium's UCB has new bidders for the unit that reportedly includes India's Cipla and Lupin.

Sources: Cipla, Lupin bid on UCB's Kremers Urban

Belgium's UCB has a generics operation in the U.S. with a 400,000-square-foot-manufacturing facility that it has been trying since last year to unload, and India's Cipla and Lupin are both reportedly in the running to buy it.